No abstract

Autoimmune hemolytic anemia (AIHA) is a rare condition in children which differs from the adult form. It is defined by immunemediated destruction of red blood cells caused by autoantibodies. Treatment depends on the type of AIHA, its severity and whether there is an underlying disorder. Rituximab is now the preferred second-line treatment for primary warm autoimmune hemolytic anemia (Waiha). Here, we present a 2-monthboy with wAIHA, resistant to steroids and cyclosporin A, who was successfully treated with rituximab. Our patient is one of the youngest cases in the literature.